Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron‐specific enolase or lactate dehydrogenase

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Respirology (Carlton South. Print)

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1440-1843.2002.00386.xPMID 11985730
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bacteria‐induced release of white cell‐ and platelet‐derived vascular endothelial growth factor in vitro

  2001cited by this paper
• Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer.

  2000cited by this paper
• Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy

  2000cited by this paper
• Laboratory Variables as Additional Staging Parameters in Patients with Small-Cell Lung Carcinoma. A Systematic Review

  1999cited by this paper
• Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops

  1998cited by this paper
• Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

  1998cited by this paper
• Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.

  1998cited by this paper
• Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles

  1998cited by this paper
• High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer

  1998cited by this paper
• Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis

  1998cited by this paper
• Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.

  1997cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

  1995cited by this paper
• Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival.

  1991cited by this paper

• Vascular endothelial growth factor and epithelial cell adhesion molecule immunoexpression in enzootic nasal adenocarcinoma of goats

  2019cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113

  2017cites this paper
• Advances in antiangiogenic treatment of small-cell lung cancer

  2017cites this paper
• Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?

  2016cites this paper
• Interrelation of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells

  2016cites this paper
• Salivary Lactate Dehydrogenase (LDH)- A Novel Technique in Oral Cancer Detection and Diagnosis.

  2016cites this paper
• Lactate dehydrogenase: An enzymatic biomarker in oral health and disease

  2015cites this paper
• Influence of tumor response on the survival of patients with extensive-stage small-cell lung cancer treated with the etoposide plus cisplatin chemotherapy regimen

  2015cites this paper
• CARCINOMA POLMONARE NON A PICCOLE CELLULE T1aN0M0: RUOLO PROGNOSTICO DELLA MICROVESSEL DENSITY

  2014cites this paper
• Serum markers in small cell lung cancer: opportunities for improvement.

  2013cites this paper
• Clinical Implications for Vascular Endothelial Growth Factor Levels among Egyptians with Pulmonary Tuberculosis

  2013cites this paper
• Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

  2012cites this paper
• Angiogenic factors in small vell lung cancer (VEGF, VEGFR-1, VEGFR-2)

  2012cites this paper
• Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

  2011influential citation
• IL-6 and VEGF in small cell lung cancer patients.

  2010cites this paper
• Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients.

  2010cites this paper
• Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis.

  2010cites this paper
• Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

  2010cites this paper
• Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

  2009cites this paper
• Molecular Prognostic and Predictive Markers in Lung Cancer

  2009cites this paper
• Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients

  2008cites this paper
• [The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer].

  2008cites this paper
• Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.

  2008cites this paper
• Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells

  2008cites this paper
• Akciğer kanserli olgularda serum "vascular endothelial growth factor (VEGF)" düzeylerinin metastazlar ve diğer tümör belirteçleri ile ilişkisinin incelenmesi

  2008cites this paper
• Vascular Endothelial Growth Factor Antibodies for Anti-Angiogenic Therapy

  2008cites this paper
• Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?

  2007cites this paper
• Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

  2007cites this paper
• Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

  2007cites this paper
• Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1α activity and vascular endothelial growth factor expression in small cell lung cancer cells

  2006cites this paper
• Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer

  2006cites this paper
• Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients.

  2005cites this paper
• The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.

  2004cites this paper
• Vascular endothelial growth factor levels in active pulmonary tuberculosis.

  2004cites this paper
• Novel approaches for the treatment of small cell lung cancer.

  2004cites this paper
• Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1284 Angiogenesis Related Markers In Non-Small Cell Lung Cancer

  2003cites this paper
• The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.

  2003cites this paper
• SU 11248 Inhibits KIT and Platelet-derived Growth Factor Receptor in Preclinical Models of Human Small Cell Lung Cancer

  2003cites this paper
• Role of Growth Factors and Biological Response Modifiers in Lung, Head and Neck and Gastrointestinal Tumors

  2003cites this paper
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  2003cites this paper
• Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis

  2003cites this paper
• Angiogenesis related markers in non-small cell lung cancer.

  2003cites this paper